Last reviewed · How we verify
Voriconazole Inhalation Powder
At a glance
| Generic name | Voriconazole Inhalation Powder |
|---|---|
| Also known as | VIP, TFF VORI |
| Sponsor | TFF Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
- Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma (PHASE1)
- Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects (PHASE1)
- Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voriconazole Inhalation Powder CI brief — competitive landscape report
- Voriconazole Inhalation Powder updates RSS · CI watch RSS
- TFF Pharmaceuticals, Inc. portfolio CI